Tetraphase Pharmaceuticals Mar 30, 2017 Previous Release PDF Add to Briefcase TETRAPHASE PHARMACEUTICALS' TP-6076 SELECTED BY CARB-X TO RECEIVE $4 MILLION IN RESEARCH FUNDING
Funding Initiative Focused On Urgent Public Health Crisis Of Antibiotic Resistance WATERTOWN, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that its pipeline candidate TP-6076 was selected to receive $4 million in research funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance. In preclinical research, TP-6076 has demonstrated potent activity against MDR bacteria, particularly those considered to be urgent or serious threats by the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).
"The selection of TP-6076 as one of the first candidates in the CARB-X portfolio highlights the potential of this early stage antibiotic compound due to its exceptional in vitro potency against two of the most dangerous organisms, carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB)," said Guy Macdonald, President and CEO of Tetraphase. "This collaboration provides important non-dilutive funding dedicated to the advancement of TP-6076, which recently completed a phase 1 single-ascending dose clinical trial and for which we plan to report data in June at the American Society for Microbiology (ASM) and Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2017 joint annual meeting."
CARB-X was launched in July 2016 and represents the world's largest public-private funding initiative to accelerate the research and development of novel drugs, diagnostics and vaccines to protect human health from the most serious bacterial threats. Companies with early stage projects were selected through a rigorous application process identifying programs that target one of the deadly antibiotic-resistant bacteria on the Serious or Urgent Threat List prepared by the CDC or on the Priority Pathogens list published by the WHO.
About TP-6076 TP-6076 is a novel, synthetic, fluorocycline antibiotic candidate generated through Tetraphase's proprietary chemistry technology. It has demonstrated potent in vitro activity against multidrug-resistant bacteria including carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii. As part of an ongoing phase 1 clinical development program, Tetraphase has evaluated intravenous TP-6076 in a phase 1 single-ascending dose clinical trial and is planning to initiate a phase 1 multiple-ascending dose clinical trial in 2017.
About CARB-X CARB-X is the world's largest public-private partnership devoted to antibacterial preclinical R&D. Funded by BARDA and Wellcome Trust, with in-kind support from NIAID, we will spend $450 million from 2017-2021 to support innovative products moving towards human clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is a charitable global public-private partnership led by Boston University School of Law. Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute and RTI International. For more information, please visit www.carb-x.org and follow us on Twitter @CARB_X.
About Tetraphase Pharmaceuticals, Inc. Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
